naringenin has been researched along with Parkinson Disease in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, MH; Ali, M; Fatima, M; Mondal, AC; Rizvi, MA | 1 |
| Agrawal, A; Dubey, N; Goyal, A; Raghav, J; Verma, A | 1 |
| Bera, K; Kundu, S; Maiti, NC; Maity, A; Mandal, AK; Misra, R; Mondal, A; Pal, U; Shome, G; Singh, A | 1 |
| Barathidasan, R; Chidambaram, SB; Essa, MM; Guillemin, GJ; Mani, S; Manivasagam, T; Sakharkar, MK; Sekar, S; Sevanan, M; Thenmozhi, AJ | 1 |
| Alam, T; Ali, J; Baboota, S; Gaba, B; Haider, MF; Khan, T; Parvez, S | 1 |
| Chen, C; He, XM; Li, DD; Li, JJ; Wang, GQ; Wei, YZ; Zhang, F | 1 |
| Klivényi, P; Plangár, I; Szalárdy, L; Vécsei, L; Zádori, D | 1 |
| Aruoma, OI; Datla, KP; Dexter, DT; Parkar, S; Rai, DK; Zbarsky, V | 1 |
1 review(s) available for naringenin and Parkinson Disease
| Article | Year |
|---|---|
Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease.
Topics: Alzheimer Disease; Antioxidants; Flavanones; Flavonoids; Humans; Neuroprotective Agents; Parkinson Disease | 2022 |
7 other study(ies) available for naringenin and Parkinson Disease
| Article | Year |
|---|---|
Naringenin alleviates paraquat-induced dopaminergic neuronal loss in SH-SY5Y cells and a rat model of Parkinson's disease.
Topics: Adenosine Triphosphate; Animals; Cell Survival; Cells, Cultured; Disease Models, Animal; Dopaminergic Neurons; Flavanones; Herbicides; Humans; Male; Membrane Potential, Mitochondrial; Neuroprotective Agents; Oxidative Stress; Paraquat; Parkinson Disease; Rats, Wistar; Substantia Nigra | 2021 |
Naringenin-Functionalized Gold Nanoparticles and Their Role in α-Synuclein Stabilization.
Topics: alpha-Synuclein; Amyloid; Gold; Humans; Metal Nanoparticles; Parkinson Disease; Spectroscopy, Fourier Transform Infrared | 2023 |
Naringenin Decreases α-Synuclein Expression and Neuroinflammation in MPTP-Induced Parkinson's Disease Model in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Encephalitis; Flavanones; Gene Expression Regulation; Glutathione; Locomotion; Male; Mice; Mice, Inbred C57BL; Muscle Strength; Neurotransmitter Agents; Nitric Oxide; Oxidative Stress; Parkinson Disease; RNA, Messenger; Tyrosine 3-Monooxygenase | 2018 |
Vitamin E Loaded Naringenin Nanoemulsion via Intranasal Delivery for the Management of Oxidative Stress in a 6-OHDA Parkinson's Disease Model.
Topics: Administration, Intranasal; Animals; Antioxidants; Behavior, Animal; Emulsions; Female; Flavanones; Levodopa; Male; Nanoparticles; Oxidative Stress; Oxidopamine; Parkinson Disease; Particle Size; Rats; Rats, Wistar; Solubility; Viscosity; Vitamin E | 2019 |
Naringenin Produces Neuroprotection Against LPS-Induced Dopamine Neurotoxicity via the Inhibition of Microglial NLRP3 Inflammasome Activation.
Topics: Animals; Dopaminergic Neurons; Flavanones; Inflammasomes; Lipopolysaccharides; Male; Microglia; Neuroprotective Agents; NLR Family, Pyrin Domain-Containing 3 Protein; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2019 |
Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allopurinol; Animals; Brain; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dopamine Agents; Drug Administration Schedule; Flavanones; Homovanillic Acid; Infusions, Parenteral; Male; Mice; Mice, Inbred C57BL; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neurotoxins; Oxidative Stress; Parkinson Disease; Silymarin; Sulfinpyrazone; Uric Acid | 2013 |
Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Curcumin; Disease Models, Animal; Dopamine; Flavanones; Flavonoids; Flavonols; Homovanillic Acid; Male; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Phenols; Quercetin; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2005 |